MedTrace Logo

A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of Liatermin

NCT00148369 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 31

Last updated 2010-02-19

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate clinical and serologic outcomes after the discontinuation of liatermin therapy as assessed by development of new clinical conditions beyond those expected in patients with advancing Parkinson's disease. In addition, the development or resolution of anti-r-metHuGDNF binding and neutralizing antibodies will be monitored.

Conditions

  • Idiopathic Parkinson's Disease

Interventions

DRUG

Safety observation

Subjects previously enrolled in a GDNF protocol observed for 2 years after discontinuation of drug.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2006-11-30
Completion
2007-09-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00148369 on ClinicalTrials.gov